Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.66 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.54 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.54 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.54 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.54 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.54 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.54 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.54 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.54 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.54 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.54 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.54 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.54 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.54 |
| ▸ | CACNA2D4 | Q7Z3S7 | 2/20 | 0.54 |
| ▸ | CACNA2D3 | Q8IZS8 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672385 | 0.93 | GPR119 (0.58) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL5672367 | 0.93 | GPR119 (0.58) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL31748202 | 0.87 | GPR119 (0.67) | GPR119NPBWR1MCHR1 | |
| SCHEMBL13993542 | 0.87 | GPR119 (0.67) | GPR119NPBWR1MCHR1KMT2A | |
| SCHEMBL5270529 | 0.86 | GPR119 (0.51) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL3180265 | 0.86 | GPR119 (0.66) | GPR119NPBWR1MCHR1 | |
| SCHEMBL940648 | 0.86 | GPR119 (0.66) | GPR119NPBWR1MCHR1 | |
| SCHEMBL22825487 | 0.86 | GPR119 (0.66) | GPR119NPBWR1MCHR1 | |
| SCHEMBL29517894 | 0.86 | GPR119 (0.66) | GPR119NPBWR1MCHR1 | |
| SCHEMBL30427128 | 0.86 | GPR119 (0.66) | GPR119NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-18 | — | — | US | disclosed |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-21 | — | — | US | disclosed |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-01 | — | — | US | disclosed |
| EP-2855449-B1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-20160376256-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9475795-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475795-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-23 | — | — | US | disclosed |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-23 | — | — | US | disclosed |
| EP-2855449-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013179024-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | WO | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-1347990-B1 | Peptides having inhibiting activity to nitric oxyde production | ASTELLAS PHARMA INC (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7129243-B2 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20040097425-A1 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | GPR119 6/4885CACNB4 1477/4885CACNA1A 77/4885 |
| US-20040097425-A1 | Peptide compounds | VIP, NOS1, NOS3 | GPR119 118/4885CACNB4 3411/4885CACNA1A 2911/4885 |
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | GPR119 6/4885CACNB4 1477/4885CACNA1A 77/4885 |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | GPR119 6/4885CACNB4 1477/4885CACNA1A 77/4885 |
| US-20160376256-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | GPR119 6/4885CACNB4 1477/4885CACNA1A 77/4885 |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | GPR119 1336/4885CACNB4 2460/4885CACNA1A 239/4885 |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | GPR119 6/4885CACNB4 1477/4885CACNA1A 77/4885 |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PGC | GPR119 6/4885CACNB4 1016/4885CACNA1A 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.